WO2021214609A1 - Pansement en pont pour l'irrigation de multiples sites tissulaires - Google Patents

Pansement en pont pour l'irrigation de multiples sites tissulaires Download PDF

Info

Publication number
WO2021214609A1
WO2021214609A1 PCT/IB2021/053130 IB2021053130W WO2021214609A1 WO 2021214609 A1 WO2021214609 A1 WO 2021214609A1 IB 2021053130 W IB2021053130 W IB 2021053130W WO 2021214609 A1 WO2021214609 A1 WO 2021214609A1
Authority
WO
WIPO (PCT)
Prior art keywords
dressing
fluid
tube
bridge
coupled
Prior art date
Application number
PCT/IB2021/053130
Other languages
English (en)
Inventor
Martin W. Steiner
Justin Rice
Original Assignee
Kci Licensing, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kci Licensing, Inc. filed Critical Kci Licensing, Inc.
Publication of WO2021214609A1 publication Critical patent/WO2021214609A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/90—Negative pressure wound therapy devices, i.e. devices for applying suction to a wound to promote healing, e.g. including a vacuum dressing
    • A61M1/92—Negative pressure wound therapy devices, i.e. devices for applying suction to a wound to promote healing, e.g. including a vacuum dressing with liquid supply means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/05—Bandages or dressings; Absorbent pads specially adapted for use with sub-pressure or over-pressure therapy, wound drainage or wound irrigation, e.g. for use with negative-pressure wound therapy [NPWT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/90—Negative pressure wound therapy devices, i.e. devices for applying suction to a wound to promote healing, e.g. including a vacuum dressing
    • A61M1/91—Suction aspects of the dressing
    • A61M1/912—Connectors between dressing and drainage tube
    • A61M1/913—Connectors between dressing and drainage tube having a bridging element for transferring the reduced pressure from the connector to the dressing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/90—Negative pressure wound therapy devices, i.e. devices for applying suction to a wound to promote healing, e.g. including a vacuum dressing
    • A61M1/91—Suction aspects of the dressing
    • A61M1/918—Suction aspects of the dressing for multiple suction locations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M3/00—Medical syringes, e.g. enemata; Irrigators
    • A61M3/02—Enemata; Irrigators
    • A61M3/0204—Physical characteristics of the irrigation fluid, e.g. conductivity or turbidity
    • A61M3/0208—Physical characteristics of the irrigation fluid, e.g. conductivity or turbidity before use
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M3/00—Medical syringes, e.g. enemata; Irrigators
    • A61M3/02—Enemata; Irrigators
    • A61M3/0204—Physical characteristics of the irrigation fluid, e.g. conductivity or turbidity
    • A61M3/022—Volume; Flow rate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
    • A61M39/22—Valves or arrangement of valves
    • A61M39/28—Clamping means for squeezing flexible tubes, e.g. roller clamps
    • A61M39/286—Wedge clamps, e.g. roller clamps with inclined guides

Definitions

  • the invention set forth in the appended claims relates generally to tissue treatment systems and more particularly, but without limitation, to fluid distribution to and/or from one or more tissue sites.
  • Negative-pressure therapy may provide a number of benefits, including migration of epithelial and subcutaneous tissues, improved blood flow, and micro deformation of tissue at a wound site. Together, these benefits can increase development of granulation tissue and reduce healing times.
  • cleansing a tissue site can be highly beneficial for new tissue growth.
  • a wound or a cavity can be washed out with a liquid solution for therapeutic purposes.
  • These practices are commonly referred to as “irrigation” and “lavage” respectively.
  • “Instillation” is another practice that generally refers to a process of slowly introducing fluid to a tissue site and leaving the fluid for a prescribed period of time before removing the fluid.
  • instillation of topical treatment solutions over a wound bed can be combined with negative- pressure therapy to further promote wound healing by loosening soluble contaminants in a wound bed and removing infectious material. As a result, soluble bacterial burden can be decreased, contaminants removed, and the wound cleansed.
  • a system for instilling at least two tissue sites can include a first dressing, a second dressing, and a bridge.
  • the bridge can be configured to fluidly couple the first dressing and the second dressing.
  • the bridge can be further configured to be fluidly coupled to an instillation source.
  • the system can include a fluid restrictor coupled to the bridge between the instillation source and the first dressing. The fluid restrictor can be operable to selectively permit fluid flow to the first dressing.
  • a system for providing therapy to a one or more tissue sites can include a first link configured to be fluidly coupled to a first tissue site, a second tissue site, and a source of fluid.
  • the system can also include a second link configured to be fluidly coupled to the first tissue site, the second tissue site, and a negative-pressure source.
  • the system can also include a regulator fluidly coupled to the first link and operable to selectively permit fluid flow to the first tissue site through the first link.
  • a method for providing instillation therapy to a tissue site is also described herein, wherein some example embodiments provide an apparatus that includes a bridge configured to be fluidly coupled to an instillation source, and a fluid restrictor operable to selectively permit fluid flow to a portion of the bridge. Fluid can be instilled to a first dressing and a second dressing through the bridge. The fluid restrictor can be operated to stop flow of instillation fluid to the first dressing. Fluid can be instilled to the second dressing.
  • Figure 1 is a functional block diagram of an example embodiment of a therapy system that can provide negative-pressure treatment and instillation treatment in accordance with this specification;
  • Figure 2 is a perspective view of a dressing that can be used with some embodiments of the therapy system of Figure 1 ;
  • Figure 3 is a functional block diagram of an example embodiment of the therapy system of Figure 1 having two dressings illustrating additional details that may be associated with some embodiments;
  • Figure 4 is a side view of a flow restrictor in a first position that can be used with some embodiments of the therapy system of Figure 1 illustrating additional details that may be associated with some embodiments;
  • Figure 5 is a sectional view of the flow restrictor of Figure 4 illustrating additional details that may be associated with some embodiments;
  • Figure 6 is a side view of the flow restrictor of Figure 4 in a second positon illustrating additional details that may be associated with some embodiments;
  • Figure 7 is a sectional view of the flow restrictor of Figure 6 illustrating additional details that may be associated with some embodiments;
  • Figure 8 is a side view of the flow restrictor of Figure 4 in a third position illustrating additional details that may be associated with some embodiments;
  • Figure 9 is a sectional view of the flow restrictor of Figure 8 illustrating additional details that may be associated with some embodiments;
  • Figure 10 is a perspective view of a portion of the therapy system of Figure 1 having a bridge and two dressings illustrating additional details that may be associated with some embodiments;
  • Figure 11A is an end view of the bridge of Figure 10 illustrating additional details that may be associated with some embodiments;
  • Figure 1 IB is another end view of the bridge of Figure 10 illustrating additional details that may be associated with some embodiments;
  • Figure 12 is a side view of a portion of the therapy system of Figure 1 illustrating additional details that may be associated with some embodiments;’
  • Figure 13 is a sectional view of the bridge of Figure 12 taken along line 13 — 13 and illustrating additional details that may be associated with some embodiments;
  • Figure 14 is a perspective view of another bridge that may be used with some embodiments of the therapy system of Figure 1 ;
  • Figure 15 is a perspective view of another bridge that may be used with some embodiments of the therapy system of Figure 1 ;
  • Figure 16 is an assembly view of another example of a bridge having a low-profile structure that may be associated with some example embodiments of the therapy system of Figure 1;
  • Figure 17 is a segmented view of an assembled portion of the bridge of Figure 16 illustrating additional details that may be associated with some embodiments;
  • Figure 18 is a segmented perspective view of portion of the bridge in the example of Figure 16, illustrating additional details that may be associated with some embodiments;
  • Figure 19 is a schematic view of an example configuration of fluid pathways in the bridge of Figure 16 as assembled, illustrating additional details that may be associated with some embodiments;
  • Figure 20 is a sectional view taken along line 20 — 20 of Figure 19 illustrating additional details that may be associated with some embodiments;
  • Figure 21 is a sectional view taken along line 21 — 21 of Figure 19 illustrating additional details that may be associated with some embodiments;
  • Figure 22 is a schematic view of the therapy system of Figure 1 disposed on a patient illustrating additional details that may be associated with some embodiments.
  • Figure 23 is a schematic view of the therapy system of Figure 1 disposed on another patient illustrating additional details that may be associated with some embodiments.
  • tissue site in this context broadly refers to a wound, defect, or other treatment target located on or within tissue, including but not limited to, a surface wound, bone tissue, adipose tissue, muscle tissue, neural tissue, dermal tissue, vascular tissue, connective tissue, cartilage, tendons, or ligaments.
  • tissue site may also refer to areas of any tissue that are not necessarily wounded or defective, but are instead areas in which it may be desirable to add or promote the growth of additional tissue. For example, negative pressure may be applied to a tissue site to grow additional tissue that may be harvested and transplanted.
  • a surface wound is a wound on the surface of a body that is exposed to the outer surface of the body, such as injury or damage to the epidermis, dermis, and/or subcutaneous layers.
  • Surface wounds may include ulcers or closed incisions, for example.
  • a surface wound, as used herein, does not include wounds within an intra-abdominal cavity.
  • a wound may include chronic, acute, traumatic, subacute, and dehisced wounds, partial thickness bums, ulcers (such as diabetic, pressure, or venous insufficiency ulcers), flaps, and grafts, for example.
  • FIG. 1 is a simplified functional block diagram of an example embodiment of a therapy system 100 that can provide negative -pressure therapy with instillation of topical treatment solutions to a tissue site in accordance with this specification.
  • the therapy system 100 may include a source or supply of negative pressure, such as a negative -pressure source 102, a dressing 104, a fluid container, such as a container 106, and a regulator or controller, such as a controller 108, for example.
  • the therapy system 100 may include sensors to measure operating parameters and provide feedback signals to the controller 108 indicative of the operating parameters.
  • the therapy system 100 may include a pressure sensor 110, an electric sensor 112, or both, coupled to the controller 108.
  • the dressing 104 may comprise or consist essentially of a tissue interface 114, a cover 116, or both in some embodiments.
  • the therapy system 100 may also include a source of instillation solution.
  • a fluid source 118 may be fluidly coupled to the dressing 104, as illustrated in the example embodiment of Figure 1.
  • the fluid source 118 may be fluidly coupled to a positive-pressure source such as the positive-pressure source 120, a negative-pressure source such as the negative-pressure source 102, or both in some embodiments.
  • a regulator such as an instillation regulator 122, may also be fluidly coupled to the fluid source 118 and the dressing 104 to ensure proper dosage of instillation solution (e.g. saline or sterile water) to a tissue site.
  • the instillation regulator 122 may comprise a piston that can be pneumatically actuated by the negative-pressure source 102 to draw instillation solution from the solution source during a negative-pressure interval and to instill the solution to a dressing during a venting interval.
  • the controller 108 may be coupled to the negative-pressure source 102, the positive-pressure source 120, or both, to control dosage of instillation solution to a tissue site.
  • the instillation regulator 122 may also be fluidly coupled to the negative-pressure source 102 through the dressing 104, as illustrated in the example of Figure 1.
  • Some components of the therapy system 100 may be housed within or used in conjunction with other components, such as sensors, processing units, alarm indicators, memory, databases, software, display devices, or user interfaces that further facilitate therapy.
  • the negative-pressure source 102 may be combined with the fluid source 118, the controller 108, and other components into a therapy unit.
  • components of the therapy system 100 may be coupled directly or indirectly.
  • the negative-pressure source 102 may be directly coupled to the container 106, and may be indirectly coupled to the dressing 104 through the container 106. Coupling may include fluid, mechanical, thermal, electrical, or chemical coupling (such as a chemical bond), or some combination of coupling in some contexts.
  • the negative-pressure source 102 may be electrically coupled to the controller 108, and may be fluidly coupled to one or more distribution components to provide a fluid path to a tissue site.
  • components may also be coupled by virtue of physical proximity, being integral to a single structure, or being formed from the same piece of material.
  • the tissue interface 114 and the cover 116 may be discrete layers disposed adjacent to each other, and may be joined together in some embodiments.
  • a distribution component is preferably detachable, and may be disposable, reusable, or recyclable.
  • the dressing 104 and the container 106 are illustrative of distribution components.
  • a fluid conductor is another illustrative example of a distribution component.
  • a tube is an elongated, cylindrical structure with some flexibility, but the geometry and rigidity may vary.
  • some fluid conductors may be molded into or otherwise integrally combined with other components.
  • Distribution components may also include or comprise interfaces or fluid ports to facilitate coupling and de-coupling other components. In some embodiments, for example, a dressing interface may facilitate coupling a fluid conductor to the dressing 104.
  • a negative-pressure supply such as the negative-pressure source 102, may be a reservoir of air at a negative pressure, or may be a manual or electrically-powered device, such as a vacuum pump, a suction pump, a wall suction port available at many healthcare facilities, or a micro pump, for example.
  • Negative pressure generally refers to a pressure less than a local ambient pressure, such as the ambient pressure in a local environment external to a sealed therapeutic environment. In many cases, the local ambient pressure may also be the atmospheric pressure at which a tissue site is located. Alternatively, the pressure may be less than a hydrostatic pressure associated with tissue at the tissue site. Unless otherwise indicated, values of pressure stated herein are gauge pressures.
  • references to increases in negative pressure typically refer to a decrease in absolute pressure, while decreases in negative pressure typically refer to an increase in absolute pressure. While the amount and nature of negative pressure applied to a tissue site may vary according to therapeutic requirements, the pressure is generally a low vacuum, also commonly referred to as a rough vacuum, between -5 mm Hg (-667 Pa) and -500 mm Hg (-66.7 kPa). Common therapeutic ranges are between - 50 mm Hg (-6.7 kPa) and -300 mm Hg (-39.9 kPa).
  • the container 106 is representative of a container, canister, pouch, or other storage component, which can be used to manage exudates and other fluids withdrawn from a tissue site.
  • a rigid container may be preferred or required for collecting, storing, and disposing of fluids.
  • fluids may be properly disposed of without rigid container storage, and a re-usable container could reduce waste and costs associated with negative-pressure therapy.
  • a controller such as the controller 108, may be a microprocessor or computer programmed to operate one or more components of the therapy system 100, such as the negative- pressure source 102.
  • the controller 108 may be a microcontroller, which generally comprises an integrated circuit containing a processor core and a memory programmed to directly or indirectly control one or more operating parameters of the therapy system 100. Operating parameters may include the power applied to the negative-pressure source 102, the pressure generated by the negative-pressure source 102, or the pressure distributed to the tissue interface 114, for example.
  • the controller 108 is also preferably configured to receive one or more input signals, such as a feedback signal, and programmed to modify one or more operating parameters based on the input signals.
  • Sensors such as the pressure sensor 110 or the electric sensor 112 are generally known in the art as any apparatus operable to detect or measure a physical phenomenon or property, and generally provide a signal indicative of the phenomenon or property that is detected or measured.
  • the pressure sensor 110 and the electric sensor 112 may be configured to measure one or more operating parameters of the therapy system 100.
  • the pressure sensor 110 may be a transducer configured to measure pressure in a pneumatic pathway and convert the measurement to a signal indicative of the pressure measured.
  • the pressure sensor 110 may be a piezoresistive strain gauge.
  • the electric sensor 112 may optionally measure operating parameters of the negative -pressure source 102, such as the voltage or current, in some embodiments.
  • the signals from the pressure sensor 110 and the electric sensor 112 are suitable as an input signal to the controller 108, but some signal conditioning may be appropriate.
  • the signal may need to be filtered or amplified before it can be processed by the controller 108.
  • the signal is an electrical signal, but may be represented in other forms, such as an optical signal.
  • the tissue interface 114 can be generally adapted to partially or fully contact a tissue site.
  • the tissue interface 114 may take many forms, and may have many sizes, shapes, or thicknesses depending on a variety of factors, such as the type of treatment being implemented or the nature and size of a tissue site.
  • the size and shape of the tissue interface 114 may be adapted to the contours of deep and irregular shaped tissue sites.
  • the cover 116 may provide a bacterial barrier and protection from physical trauma.
  • the cover 116 may also be constructed from a material that can reduce evaporative losses and provide a fluid seal between two components or two environments, such as between a therapeutic environment and a local external environment.
  • the cover 116 may be, for example, an elastomeric film or membrane that can provide a seal adequate to maintain a negative pressure at a tissue site for a given negative-pressure source.
  • the cover 116 may have a high moisture- vapor transmission rate (MVTR) in some applications.
  • the MVTR may be at least about 300 g/m 2 per twenty-four hours in some embodiments.
  • the cover 116 may be a polymer drape, such as a polyurethane film, that is permeable to water vapor but impermeable to liquid.
  • a polymer drape such as a polyurethane film
  • Such drapes typically have a thickness in the range of about 25 microns to about 50 microns.
  • the permeability generally should be low enough that a desired negative pressure may be maintained.
  • the cover 116 may comprise, for example, one or more of the following materials: hydrophilic polyurethane; cellulosics; hydrophilic polyamides; polyvinyl alcohol; polyvinyl pyrrolidone; hydrophilic acrylics; hydrophilic silicone elastomers; an INSPIRE 2301 material from Coveris Advanced Coatings of Wrexham, United Kingdom having, for example, an MVTR (inverted cup technique) of about 14400 g/m 2 /24 hours and a thickness of about 30 microns; a thin, uncoated polymer drape; natural rubbers; polyisoprene; styrene butadiene rubber; chloroprene rubber; polybutadiene; nitrile rubber; butyl rubber; ethylene propylene rubber; ethylene propylene diene monomer; chlorosulfonated polyethylene; polysulfide rubber; polyurethane (PU); EVA film; co polyester; silicones; a silicone drape; a
  • An attachment device may be used to attach the cover 116 to an attachment surface, such as undamaged epidermis, a gasket, or another cover.
  • the attachment device may take many forms.
  • an attachment device may be a medically-acceptable, pressure -sensitive adhesive configured to bond the cover 116 to epidermis around a tissue site.
  • some or all of the cover 116 may be coated with an adhesive, such as an acrylic adhesive, which may have a coating weight between about 25 grams per square meter (g.s.m.) and about 65 g.s.m. Thicker adhesives, or combinations of adhesives, may be applied in some embodiments to improve the seal and reduce leaks.
  • Other example embodiments of an attachment device may include a double-sided tape, paste, hydrocolloid, hydrogel, silicone gel, or organ gel.
  • the fluid source 118 may also be representative of a container, canister, pouch, bag, or other storage component, which can provide a solution for instillation therapy.
  • Compositions of solutions may vary according to a prescribed therapy, but examples of solutions that may be suitable for some prescriptions include hypochlorite-based solutions, silver nitrate (0.5%), sulfur-based solutions, biguanides, cationic solutions, and isotonic solutions.
  • the fluid mechanics of using a negative-pressure source to reduce pressure in another component or location, such as within a sealed therapeutic environment can be mathematically complex.
  • the basic principles of fluid mechanics applicable to negative-pressure therapy and instillation are generally well-known to those skilled in the art, and the process of reducing pressure may be described illustratively herein as “delivering,” “distributing,” or “generating” negative pressure, for example.
  • downstream typically implies a position in a fluid path relatively closer to a source of negative pressure or further away from a source of positive pressure.
  • upstream implies a position relatively further away from a source of negative pressure or closer to a source of positive pressure.
  • inlet or outlet in such a frame of reference. This orientation is generally presumed for purposes of describing various features and components herein.
  • the fluid path may also be reversed in some applications (such as by substituting a positive-pressure source for a negative-pressure source) and this descriptive convention should not be construed as a limiting convention.
  • Negative pressure applied across the tissue site through the tissue interface 114 in the sealed therapeutic environment can induce macro-strain and micro-strain in the tissue site. Negative pressure can also remove exudate and other fluid from a tissue site, which can be collected in container 106.
  • the controller 108 may receive and process data from one or more sensors, such as the pressure sensor 110 and the electric sensor 112. The controller 108 may also control the operation of one or more components of the therapy system 100 to manage the pressure delivered to the tissue interface 114.
  • controller 108 may include an input for receiving a desired target pressure and may be programmed for processing data relating to the setting and inputting of the target pressure to be applied to the tissue interface 114.
  • the target pressure may be a fixed pressure value set by an operator as the target negative pressure desired for therapy at a tissue site and then provided as input to the controller 108.
  • the target pressure may vary from tissue site to tissue site based on the type of tissue forming a tissue site, the type of injury or wound (if any), the medical condition of the patient, and the preference of the attending physician.
  • the controller 108 can operate the negative-pressure source 102 in one or more control modes based on the target pressure and may receive feedback from one or more sensors to maintain the target pressure at the tissue interface 114.
  • FIG. 2 is an assembly view of an example of the dressing 104 of Figure 1, illustrating additional details that may be associated with some embodiments.
  • the dressing 104 includes the tissue interface 114 and the cover 116.
  • the dressing 104 may also include a release liner 202 to protect an optional adhesive on a portion of the cover 116 prior to use.
  • the release liner 202 may also provide stiffness to assist with, for example, deployment of the dressing 104.
  • the release liner 202 may be, for example, a casting paper, a film, or polyethylene. Further, in some embodiments, the release liner 202 may be a polyester material such as polyethylene terephthalate (PET), or similar polar semi-crystalline polymer.
  • PET polyethylene terephthalate
  • a polar semi-crystalline polymer for the release liner 202 may substantially preclude wrinkling or other deformation of the dressing 104.
  • the polar semi-crystalline polymer may be highly orientated and resistant to softening, swelling, or other deformation that may occur when brought into contact with components of the dressing 104, or when subjected to temperature or environmental variations, or sterilization.
  • a release agent may be disposed on a side of the release liner 202 that is configured to contact the tissue interface 114.
  • the release agent may be a silicone coating and may have a release factor suitable to facilitate removal of the release liner 202 by hand and without damaging or deforming the dressing 104.
  • the release agent may be a fluorocarbon or a fluorosilicone, for example.
  • the release liner 202 may be uncoated or otherwise used without a release agent.
  • Figure 2 also illustrates one example of a fluid conductor 204 and a dressing interface 206.
  • the fluid conductor 204 may be a flexible tube, which can be fluidly coupled on one end to the dressing interface 206.
  • the dressing interface 206 may be an elbow connector, as shown in the example of Figure 2, which can be placed over an aperture 208 in the cover 116 to provide a fluid path between the fluid conductor 204 and the tissue interface 114.
  • Some patients may have multiple tissue sites that can benefit from both negative- pressure therapy and instillation therapy. And many negative -pressure therapy systems can be adapted to service multiple tissue sites.
  • the negative-pressure source 102 may be connected to multiple tissue sites and operated to draw fluid from each tissue site. Sensors and valve systems can be combined with the negative-pressure source 102 to effectively and successfully provide negative- pressure therapy to each tissue site.
  • Individual instillation sources may face challenges providing instillation therapy to more than one tissue site. If the tissue sites to be treated are not of generally equal size, a single instillation source may not be adapted to provide instillation therapy.
  • a large wound having an unusual configuration may require substantially more fluid during each instillation therapy cycle than other smaller sites being simultaneously treated.
  • the instillation source may inadvertently oversupply fluid to the smaller tissue sites. Overfilling can potentially cause failure of the dressing associated with the smaller tissue site. For example, overfilling can cause an increase in pressure at the tissue site that can cause the seal between the sealing member of a dressing and the epidermis surrounding the tissue site to fail, i.e., causing a blow out of the dressing.
  • Therapy systems may incorporate complex systems to determine the total volume of fluid to deliver to each tissue site to provide proper instillation without causing dressing failure. Often, the therapy system incorporates additional sensors located at the dressing to determine that each tissue site has the appropriate level of fluid. These additional sensors and monitoring systems can significantly increase the cost of instillation therapy, placing the benefits of instillation therapy out of reach for some facilities and patients.
  • Some systems designed to treat multiple tissue sites include a dressing intended to simultaneously cover the treated the tissue sites.
  • the tissue sites may be adjacent to each other or in close proximity.
  • a single dressing may be used to cover all of the tissue sites. Therapy can be provided to all of the tissue sites through the single dressing. While negative-pressure therapy can efficiently and successfully be provided in this manner, instillation therapy may again face challenges.
  • fluid may not be properly distributed to each tissue site.
  • a tissue site that is positioned lower on the body for example, on a leg or lower abdomen may be gravitationally lower than a tissue site located on a chest or upper back. Gravity may draw more fluid to tissue sites that are gravitationally lower. These tissue sites may have fluid pool at the tissue site to the detriment of gravitationally higher tissue sites.
  • instillation therapy systems do not have a mechanism to control how the fluid is distributed between each the multiple tissue sites.
  • the therapy system 100 which can provide negative -pressure therapy and instillation therapy to multiple tissue sites.
  • the therapy system 100 permits fluid management of both negative-pressure therapy systems and instillation therapy systems without requiring changeover of systems.
  • the therapy system 100 can provide management of fluids for two tissue sites having uneven shapes, differing sizes, and differing volumes, or for a tissue site involving a joint by providing a flow control device to permit metering of fluid to at least one of the tissue sites.
  • specific flow rates can be selected for at least one of the tissue sites.
  • the therapy system 100 can also provide bridging capability for tissue sites having fragile skin that can make bridging of two or more tissue sites difficult or uncomfortable for the patient. Simultaneous treatment of multiple tissue sites can also be accomplished without requiring additional layers, such as a protective layer to be included with the dressing.
  • FIG 3 is a schematic view of a portion of the therapy system 100 illustrating additional details that may be associated with some embodiments of the therapy system 100 having more than one dressing 104.
  • the therapy system 100 includes the container 106 and the fluid source 118.
  • Two dressings 104 are illustrated in the therapy system 100 in Figure 3, a first dressing 302 and a second dressing 304.
  • Each of the first dressing 302 and the second dressing 304 includes a tissue interface 114 and a cover 116.
  • the first dressing 302 and the second dressing 304 can be fluidly coupled to the container 106 and to the negative-pressure source 102 through the container 106.
  • first dressing 302 and the second dressing 304 can be fluidly coupled to the container 106 with a fluid conductor, such as a tube.
  • first dressing 302 and the second dressing 304 can each be independently fluidly coupled to the container 106.
  • first dressing 302 and the second dressing 304 can be fluidly coupled to each other, and a secondary fluid conductor can fluidly couple the first dressing 302 and the second dressing 304 to the container 106.
  • the first dressing 302 and the second dressing 304 can also be fluidly coupled to the fluid source 118.
  • the first dressing 302 and the second dressing 304 can be fluidly coupled to the fluid source 118 with a fluid conductor, such as a tube.
  • the first dressing 302 and the second dressing 304 can each be independently fluidly coupled to the fluid source 118.
  • the first dressing 302 and the second dressing 304 can be fluidly coupled to each other, and a secondary fluid conductor can fluidly couple the first dressing 302 and the second dressing 304 to the fluid source 118.
  • the therapy system 100 also includes a flow restrictor 306.
  • the first dressing 302 is directly fluidly coupled to the fluid source 118
  • the second dressing 304 is fluidly coupled to the flow restrictor 306 and to the fluid source 118 through the flow restrictor 306.
  • a flow limiter such as the flow restrictor 306, can be a roller clamp, a screw clamp, a slide clamp, or a needle valve, for example.
  • a roller clamp may be a device equipped with a small roller that can be rolled to close off or open a tube associated with the roller clamp. In some embodiments, the roller clamp can be positioned to restrict the flow of fluid through the tube without fully closing the tube.
  • a screw clamp can be a device associated with a tube having a screw capable of closing and opening the tube. In some embodiments, a screw clamp can be manipulated to restrict flow through the tube without fully closing the tube.
  • a slide clamp is a device having a slide associated with a tube.
  • a needle valve can be valve having a long, tapered, needlelike point on the end of the valve stem.
  • the needle can be feathered through an orifice of the valve before the needle seats.
  • the needle can gradually increase or decrease the size of the opening to restrict fluid flow through the orifice.
  • FIG. 4 is a schematic view of a portion of the therapy system 100, illustrating additional details that may be associated with some embodiments.
  • the fluid source 118, the first dressing 302, and the second dressing 304 can be fluidly coupled to a T-fitting 402.
  • the T-fitting 402 can be a fluid conductor having three fluid couplings disposed at three separate ends.
  • the T-fitting 402 can be configured to provide fluid communication between each of the three ends.
  • the T-fitting 402 can have a first arm 404 having an interior end and an exterior end.
  • the exterior end can be configured to be coupled to the fluid source 118.
  • the first arm 404 can have a lumen extending through the first arm 404 from the interior end to the exterior end.
  • the T-fitting 402 can have a second arm 406 having an interior end and an exterior end.
  • the second arm 406 can have a lumen extending through the second arm 406 from the interior end to the exterior end.
  • the exterior end can be configured to be coupled to the first dressing 302.
  • the second arm 406 can be coupled to the fluid conductor 204 of the first dressing 302 and the lumen of the second arm 406 can be in fluid communication with a lumen of the fluid conductor 204.
  • the T-fitting 402 can have a third arm 408 having an interior end and an exterior end.
  • the third arm 408 can have a lumen extending through the third arm 408.
  • the exterior end can be configured to be coupled to the second dressing 304.
  • the third arm 408 can be coupled to the fluid conductor 204 of the second dressing 304 and the lumen of the third arm 408 can be in fluid communication with a lumen of the fluid conductor 204.
  • interior ends of the first arm 404, the second arm 406, and the third arm 408 can be coupled to each other, and the lumens of the first arm 404, the second arm 406, and the third arm 408 can be in fluid communication with each other.
  • the first arm 404 is perpendicular to the second arm 406 and the third arm 408.
  • the second arm 406 can be perpendicular to the first arm 404 and the third arm 408.
  • the third arm 408 can be perpendicular to the first arm 404 and the second arm 406.
  • the first arm 404, the second arm 406, and the third arm 408 can be coupled to each other at a non-normal angle.
  • the first arm 404, the second arm 406, and the third arm 408 can be equidistantly spaced from each other.
  • the flow restrictor 306 can be associated with the third arm 408.
  • the flow restrictor 306 can be configured to selectively permit, prevent, or restrict flow through the lumen of the third arm 408 from the interior end to the exterior end.
  • the flow restrictor 306 can be placed between the junction of the interior ends of the third arm 408, the second arm 406, and the first arm 404 and the second dressing 304.
  • the flow restrictor 306 can be proximate to the junction of the interior ends of the third arm 408, the second arm 406, and the first arm 404. Placement of the flow restrictor 306 proximate to the junction of the interior ends may decrease the instances of generating a pressure point and causing further tissue damage.
  • the flow restrictor 306 may be further from the tissue site and the patient, allowing the patient to move or turn without trapping the flow restrictor 306 between the patient and another object such as a bed.
  • the flow restrictor 306 can be positioned on the fluid conductor 204 of the second dressing 304.
  • Figure 5 is a sectional view of a portion of the third arm 408 and the flow restrictor 306, illustrating additional details associated with some embodiments.
  • the flow restrictor 306 can be a device configured to be coupled to the third arm 408 or a conduit, such as the fluid conductor 204.
  • the third arm 408 can have a lumen 518 extending through the third arm 408.
  • the lumen 518 can be a flow passaged permitting fluid flow through the third arm 408.
  • the lumen 518 may provide fluid communication between the junction of the interior ends of the first arm 404, the second arm 406, and the third arm 408 and the exterior end of the third arm 408.
  • the flow restrictor 306 may be a clamping device configured to compress the third arm 408 to reduce an internal diameter of the third arm 408, restricting the lumen 518.
  • the flow restrictor 306 can have a base 502 coupled to at least one wall 504.
  • the at least one wall 504 can be perpendicular to the base 502.
  • the at least one wall 504 may be coupled to the base 502 at other angles.
  • the base 502 can have a width substantially similar to an outer diameter of the third arm 408.
  • the at least one wall 504 may have a first end 506 and a second end 508.
  • the second end 508 may have a height measured from the base 502 that is greater than the height of the first end 506.
  • the at least one wall 504 can have a height at the first end that is substantially similar to an outer diameter of the third arm 408.
  • the at least one wall 504 can have a height at the second end that is substantially similar to twice an outer diameter of the third arm 408.
  • the at least one wall 504 may slope from the second end 508 to the first end 506.
  • the at least one wall 504 may have a maximum height at the second end 508 and a minimum height at the first end 506.
  • a channel 510 can be formed on a surface of the at least one wall 504.
  • the channel 510 can be disposed in the at least one wall 504 in a surface of the at least one wall 504 facing the third arm 408.
  • the at least one wall 504 may have a first surface or exterior surface configured to face away from the third arm 408 if the flow restrictor 306 is coupled to the third arm 408.
  • the at least one wall 504 may have a second surface or interior surface configured to face toward the third arm 408 if the flow restrictor 306 is coupled to the third arm 408.
  • the channel 510 can be disposed in the interior surface of the at least one wall 504.
  • the channel 510 may extend from the second end 508 to the first end 506.
  • the channel 510 may have a slope substantially equivalent and parallel to the slope of the at least one wall 504 between the second end 508 and the first end 506. In some embodiments, the channel 510 may have a depth less than athickness of the at least one wall 504. In other embodiments, the channel 510 may extend through the at least one wall 504. [0070]
  • the flow restrictor 306 can include a roller 512.
  • the roller 512 can be a mechanical apparatus configured to cooperate with the base 502 and the at least one wall 504 to apply a clamping force to third arm 408. The clamping force can restrict or prevent fluid flow through the third arm 408. In some embodiments, the roller 512 may be a disc 513 having a diameter 514 and a thickness.
  • the roller 512 can also include an axle 516.
  • the axle 516 may pass through a center of the roller 512.
  • the disc 513 and the axle 516 may be rotate about an axis of the axle 516.
  • An end of the axle 516 may be received by the channel 510 of the at least one wall 504.
  • the disc 513 may be in contact with an exterior surface of the third arm 408.
  • the diameter 514 of the disc 513 can be selected to permit the third arm 408 to be disposed between the disc 513 and the base 502 without restricting fluid flow through the lumen 518 of the third arm 408.
  • the flow restrictor 306 can be in a first position or an open position. In the first position, the lumen 518 of the third arm 408 may be open, permitting unrestricted fluid flow through the third arm 408.
  • Figure 6 is a schematic view of a portion of the therapy system 100, illustrating additional details that may be associated with some embodiments of the flow restrictor 306 in a second position.
  • the second position may also be referred to as a closed position.
  • the roller 512 can be positioned proximate to the first end 506 of the at least one wall 504.
  • the disc 513 can be rolled about the axis of the axle 516, causing the axle 516 to translate through the channel 510.
  • the slope of the channel 510 from the second end 508 to the first end 506 can cause the roller 512 to move toward the base 502. Movement of the roller 512 toward the base 502 can cause a perimeter of the disc 513 to contact an exterior of the third arm 408.
  • the disc 513 can compress the third arm 408 between the disc 513 and the base 502.
  • Figure 7 is a sectional view of a portion of the third arm 408 and the flow restrictor 306, illustrating additional details associated with some embodiments of the flow restrictor 306 in the second position.
  • the roller 512 can compress the third arm 408 between the roller 512 and the base 502. Compressing the third arm 408 may force opposing sides of the inner diameter of the third arm 408 into contact, blocking fluid flow through the lumen 518of the third arm 408.
  • the disc 513 can have the diameter 514 sized to cause complete closure of the lumen 518 of the third arm 408.
  • the diameter 514 of the disc 513 can be equal to twice the distance from a top of the base 502 to an end of the channel 510 adjacent the first end 506 plus twice a wall thickness of the third arm 408.
  • the thickness of the disc 513 can be selected to cause complete closure of the lumen 518 of the third arm 408.
  • Figure 8 is a schematic view of a portion of the therapy system 100, illustrating additional details that may be associated with some embodiments of the flow restrictor 306 in a third position.
  • the roller 512 can be positioned between the first end 506 and the second end 508 of the at least one wall 504.
  • the disc 513 can be rolled about the axis of the axle 516, causing the axle 516 to translate through the channel 510.
  • the roller 512 can also move toward the base 502, compressing the third arm 408 between the roller 512 and the base 502.
  • Figure 9 is a sectional view of a portion of the third arm 408 and the flow restrictor 306, illustrating additional details associated with some embodiments of the flow restrictor 306 in the third position.
  • the roller 512 can compress the third arm 408 between the roller 512 and the base 502. Compressing the third arm 408 may force opposing sides of the inner diameter of the third arm 408 toward each other, partially blocking fluid flow through the lumen 518 of the third arm 408 and decreasing flow through the lumen 518 of the third arm 408.
  • the roller 512 can be variably disposed between the first end 506 and the second end 508.
  • each rotation of the disc 513 about the axis of the axle 516 can translate the roller 512 a portion of the distance between the first end 506 and the second end 508 of the at least one wall 504.
  • Each rotation of the disc 513 moving the roller 512 from the second end 508 toward the first end 506 can also move the roller 512 closer to the base 502.
  • the disc 513 will increasingly compress the third arm 408 so that the lumen 518 becomes more restricted as the roller 512 approaches the first end 506.
  • the amount of fluid flow through the lumen 518 can be selected.
  • FIG 10 is a perspective view of another embodiment of the therapy system 100 of Figure 1, illustrating additional details that may be associated with some embodiments.
  • the therapy system 100 can provide both negative-pressure therapy and instillation therapy.
  • the therapy system 100 can include the first dressing 302, the second dressing 304, the flow restrictor 306, and the T-fitting 402.
  • the first arm 404 of the T-fitting 402 can be fluidly coupled to the fluid source 118, and the second arm 406 of the T-fitting 402 can be fluidly coupled to the first dressing 302 through a first connector 1012.
  • the first connector 1012 may be similar to and operate as described above with respect to the dressing interface 206.
  • the third arm 408 can be fluidly coupled to the second dressing 304 through a second connector 1014.
  • the first connector 1012 and the second connector 1014 can be a V.A.C. VERAT.R.A.C.TM Pad, a V.A.C.VERA T.R.A.C.TM Pad, or similar.
  • the second connector 1014 can be similar to and operate as described above with respect to the dressing interface 206.
  • the flow restrictor 306 can be coupled to the third arm 408 of the T-fitting 402 and be operable to restrict fluid flow through the third arm 408.
  • the therapy system 100 can include a fluid connection permitting the negative-pressure source 102 to be fluidly coupled to both the first dressing 302 and the second dressing 304.
  • the fluid connection can be formed by a link or a bridge 1002.
  • the bridge 1002 can have a first end 1004 and a second end 1006.
  • the first end 1004 can be opposite the second end 1006.
  • the bridge 1002 can have a length 1010 between the first end 1004 and a second end 1006.
  • the first end 1004 of the bridge 1002 can be fluidly coupled to the first dressing 302.
  • the first end 1004 of the bridge 1002 can be fluidly coupled to the first dressing 302 through the first connector 1012.
  • the second end 1006 can be fluidly coupled to the second dressing 304.
  • the second end 1006 can be fluidly coupled to the second dressing 304 through a third connector 1016.
  • the third connector 1016 can be a V.A.C. VERAT.R.A.C.TM Pad, a V.A.C.VERA T.R.A.C.TM Pad, or similar.
  • a tube 1008 can be fluidly coupled to the bridge 1002 between the first end 1004 and the second end 1006. In some embodiments, the tube 1008 can be fluidly coupled to the negative -pressure source 102.
  • the bridge 1002 may comprise a T-fitting and additional tube sets.
  • the tube 1008 may be fluidly coupled to a first arm of a T-fitting.
  • Another tube may fluidly couple a second arm of the T-fitting to the first dressing 302, and yet another tube may fluidly couple athird arm ofthe T-fitting to the second dressing 304.
  • Fluid may be drawn from the first dressing 302 and the second dressing 304 through the tubes fluidly coupled to the second arm and the third arm of the T-fitting through the first arm of the T-fitting that is fluidly coupled to the tube 1008.
  • Figure 11A is an end view of the bridge 1002, illustrating additional details that may be associated with some embodiments.
  • the first connector 1012 can be configured to provide a fluid coupling for two fluid sources.
  • the first connector 1012 can include a first tube 1102 configured to be fluidly coupled to a negative-pressure source, such as the negative-pressure source 102, and a second tube 1104 configured to be fluidly coupled to a fluid source, such as the fluid source 118.
  • the first tube 1102 and the second tube 1104 may each be similar to and operate as describe above with respect to the fluid conductor 204.
  • Figure 11A also illustrates the first end 1004 of the bridge 1002.
  • the first end 1004 of the bridge 1002 can be enclosed and include a fluid conductor, such as a tube 1106.
  • the tube 1106 can have a first end fluidly coupled to the first end 1004 of the bridge 1002.
  • the first end of the tube 1106 can be coupled to the first end 1004 of the bridge 1002 so that fluid may flow between the bridge 1002 and the tube 1106.
  • the first end of the tube 1106 can be inserted into an interior of the bridge 1002 to permit the first end 1004 to be fluidly coupled to another distribution component, such as the first dressing 302.
  • the tube 1106 can be coupled, for example with a tube connector 1108, to the first tube 1102.
  • the tube connector 1108 provides a physical connection between the tube 1106 and the first tube 1102 to permit fluid communication between the tube 1106 and the first tube 1102.
  • the first tube 1102 can be fluidly coupled to the first connector 1012 of the first dressing 302.
  • the second arm 406 of the T-fitting 402 can be fluidly coupled to the second tube 1104 with a connector 1110.
  • the connector 1110 provides a physical connection between the second arm 406 and the second tube 1104 to permit fluid communication between the second arm 406 and the second tube 1104.
  • the second tube 1104 can then be fluidly coupled to the first connector 1012 of the first dressing 302.
  • Figure 1 IB is an end view of the bridge 1002, illustrating additional details that may be associated with some embodiments.
  • the second connector 1014 can include a third tube 1112 configured to be fluidly coupled to a fluid source, such as the fluid source 118.
  • the third connector 1016 can include a fourth tube 1114 configured to be fluidly coupled to a negative- pressure source, such as the negative-pressure source 102.
  • a negative-pressure source such as the negative-pressure source 102.
  • the third tube 1112 and the fourth tube 1114 may each be similar to and operate as describe above with respect to the fluid conductor 204.
  • Figure 11B also illustrates the second end 1006 of the bridge 1002.
  • the second end 1006 of the bridge 1002 can be enclosed and include a fluid conductor, such as a tube 1116.
  • the tube 1116 can have a first end fluidly coupled to the second end 1006 of the bridge 1002.
  • the first end of the tube 1116 can be coupled to the second end 1006 of the bridge 1002 so that fluid may flow between the bridge 1002 and the tube 1116.
  • the first end of the tube 1116 can be inserted into an interior of the bridge 1002 to permit the second end 1006 to be fluidly coupled to another distribution component, such as the second dressing 304.
  • the tube 1116 can be coupled, for example with a tube connector 1118, to the fourth tube 1114.
  • the tube connector 1118 provides a physical connection between the tube 1116 and the fourth tube 1114 to permit fluid communication between the tube 1116 and the fourth tube 1114.
  • the fourth tube 1114 can be fluidly coupled to the third connector 1016 of the second dressing 304.
  • the third arm 408 of the T-fitting 402 can be fluidly coupled to the third tube 1112 with a connector 1120.
  • the connector 1120 provides a physical connection between the third arm 408 and the third tube 1112 to permit fluid communication between the third arm 408 and the third tube 1112.
  • the third tube 1112 can then be fluidly coupled to the second connector 1014 of the second dressing 304.
  • FIG 12 is a side view of a portion of the therapy system 100 of Figure 10 illustrating additional details that may be associated with some embodiments.
  • the tube 1008 can have an end 1202 that can be inserted into the bridge 1002.
  • the end 1202 can be open and have aplurality of fenestrations 1204.
  • the plurality of fenestrations 1204 can be equidistantly spaced around a circumference of the end 1202. In other embodiments, the plurality of fenestrations 1204 can be preferentially disposed in a particular areas of the end 1202.
  • the therapy system 100 can include a mounting bracket 1206.
  • the mounting bracket 1206 can receive the bridge 1002, the flow restrictor 306, and the T-fitting 402.
  • the mounting bracket 1206 can contain the bridge 1002, the flow restrictor 306, and the T-fitting 402, preventing entanglement.
  • the flow restrictor 306 can include two at least one wall 504.
  • a second wall 504 can be disposed on an opposite side of the base 502 from the at least one wall 504.
  • FIG 13 is a sectional view of the bridge 1002 taken along line 13 — 13 of Figure 12, illustrating additional details that can be associated with some embodiments.
  • the bridge 1002 can be formed from a foam material wrapped in a drape material.
  • the bridge 1002 can comprise a fluid distributor 1302 encapsulated by a sealing member 1304.
  • the fluid distributor 1302 can have a height 1306, a width 1308, and the length 1010.
  • the fluid distributor 1302 can be cellular foam, open-cell foam, reticulated foam, or porous tissue collections, may be used to form the fluid distributor 1302.
  • the fluid distributor 1302 may be formed of V.A.C. ® GRANUFOAMTM Dressing, grey foam, or Zotefoam.
  • Grey foam may be a polyester polyurethane foam having about 60 pores per inch (ppi).
  • Zotefoam may be a closed-cell crosslinked polyolefin foam.
  • the fluid distributor 1302 may be an open-cell, reticulated polyurethane foam such as V.A.C. ® GRANUFOAMTM Dressing available from Kinetic Concepts, Inc.
  • the fluid distributor 1302 may be an open-cell, reticulated polyurethane foam such as a V.A.C. VERAFLOTM dressing, also available from Kinetic Concepts, Inc., of San Antonio, Texas.
  • the fluid distributor 1302 may have a 25% compression load deflection of at least 0.35 pounds per square inch, and the 65% compression load deflection may be at least 0.43 pounds per square inch.
  • the tensile strength of the fluid distributor 1302 may be at least 10 pounds per square inch.
  • the fluid distributor 1302 may have a tear strength of at least 2.5 pounds per inch.
  • the fluid distributor 1302 may be formed from a foam that is mechanically or chemically compressed, often as part of a thermoforming process, to increase the density of the foam at ambient pressure.
  • a foam that is mechanically or chemically compressed may be referred to as a compressed foam or a felted foam.
  • a compressed foam may be characterized by a firmness factor (FF) that is defined as a ratio of the density of a foam in a compressed state to the density of the same foam in an uncompressed state.
  • FF firmness factor
  • 5 may refer to a compressed foam having a density at ambient pressure that is five times greater than a density of the same foam in an uncompressed state at ambient pressure.
  • a compressed or felted foam may have a firmness factor greater than 1.
  • Mechanically or chemically compressing a foam may reduce a thickness of the foam at ambient pressure when compared to the same foam that has not been compressed. Reducing a thickness of a foam by mechanical or chemical compression may increase a density of the foam, which may increase the firmness factor (FF) of the foam. Increasing the firmness factor (FF) of a foam may increase a stiffness of the foam in a direction that is parallel to a thickness of the foam. For example, increasing a firmness factor (FF) of the fluid distributor 1302 may increase a stiffness of the fluid distributor 1302 in a direction that is parallel to the thickness 212 of the fluid distributor 1302. In some embodiments, a compressed foam may be a compressed V.A.C. ® GRANUFOAMTM Dressing.
  • V.A.C. ® GRANUFOAMTM Dressing may have a density of about 0.03 grams per centimeter 3 (g/cm 3 ) in its uncompressed state. If the V.A.C. ® GRANUFOAMTM Dressing is compressed to have a firmness factor (FF) of 5, the V.A.C. ® GRANUFOAMTM Dressing may be compressed until the density of the V.A.C. ® GRANUFOAMTM Dressing is about 0.15g/cm 3 . V.A.C. VERAFLOTM dressing may also be compressed to form a compressed foam having a firmness factor (FF) up to 5.
  • FF firmness factor
  • the sealing member 1304 can be similar to the cover 116.
  • the sealing member 1304 may provide a bacterial barrier and protection from physical trauma.
  • the sealing member 1304 may also be constructed from a material that can reduce evaporative losses and provide a fluid seal between two components or two environments, such as between a therapeutic environment and a local external environment.
  • the sealing member 1304 may be, for example, an elastomeric film or membrane that can provide a seal adequate to maintain a negative pressure at a tissue site for a given negative-pressure source.
  • the sealing member 1304 may have a high moisture-vapor transmission rate (MVTR) in some applications.
  • the MVTR may be at least about 300 g/m 2 per twenty- four hours in some embodiments.
  • the sealing member 1304 may be a polymer drape, such as a polyurethane film, that is permeable to water vapor but impermeable to liquid.
  • a polymer drape such as a polyurethane film
  • Such drapes typically have a thickness in the range of about 25 microns to about 50 microns.
  • the permeability generally should be low enough that a desired negative pressure may be maintained.
  • the sealing member 1304 may comprise, for example, one or more of the following materials: hydrophilic polyurethane; cellulosics; hydrophilic polyamides; polyvinyl alcohol; polyvinyl pyrrolidone; hydrophilic acrylics; hydrophilic silicone elastomers; an INSPIRE 2301 material from Coveris Advanced Coatings of Wrexham, United Kingdom having, for example, an MVTR (inverted cup technique) of about 14400 g/m 2 /24 hours and a thickness of about 30 microns; a thin, uncoated polymer drape; natural rubbers; polyisoprene; styrene butadiene rubber; chloroprene rubber; polybutadiene; nitrile rubber; butyl rubber; ethylene propylene rubber; ethylene propylene diene monomer; chlorosulfonated polyethylene; polysulfide rubber; polyurethane (PU); EVA film; co polyester; silicones; a silicone drape;
  • An attachment device may be used to attach the sealing member 1304 to an attachment surface, such as undamaged epidermis, a gasket, another cover, or the fluid distributor 1302.
  • the attachment device may take many forms.
  • an attachment device may be a medically- acceptable, pressure-sensitive adhesive configured to bond the sealing member 1304 to epidermis around a tissue site.
  • some or all of the sealing member 1304 may be coated with an adhesive, such as an acrylic adhesive, which may have a coating weight between about 25 grams per square meter (g.s.m.) and about 65 g.s.m. Thicker adhesives, or combinations of adhesives, may be applied in some embodiments to improve the seal and reduce leaks.
  • the sealing member 1304 can surround the fluid distributor 1302.
  • the sealing member 1304 can enclose the fluid distributor 1302 by covering the height 1306, the width 1308, and the length 1010 of the fluid distributor 1302.
  • the sealing member 1304 can cover and seal the first end 1004 and the second end 1006 of the bridge 1002.
  • the sealing member 1304 can create a sealed environment or lumen within the fluid distributor 1302 that is isolated from the ambient environment and prevent fluid communication across the first end 1004 and the second end 1006 of the bridge 1002.
  • the mounting bracket 1206 can include a plurality of walls.
  • the mounting bracket 1206 can include a bottom wall 1310, sidewalls 1312, and atop wall 1314.
  • the sidewalls 1312 can be coupled to the bottom wall 1310 at a first end of each sidewall 1312.
  • the bottom wall 1310 may have a width equal to a width of the bridge 1002.
  • the sidewalls 1312 may have a height equal to or greater than a height of the bridge 1002.
  • the top wall 1314 can be coupled to the sidewalls 1312 at ends of the sidewalls 1312 that are opposite the bottom wall 1310.
  • the top wall 1314 may be parallel to the bottom wall 1310.
  • the top wall 1314 can be coupled to the flow restrictor 306.
  • the base 502 can be coupled to the top wall 1314.
  • the mounting bracket 1206 can be formed from a semi-rigid material, for example, rubber, silicone, plastic, metal, or other similar material.
  • the mounting bracket 1206 can receive the bridge 1002, the T-fitting 402, and the flow restrictor 306.
  • the mounting bracket 1206 can maintain a spatial relationship between the bridge 1002, the T-fitting 402, and the flow restrictor 306 for use and operation of the same.
  • the second dressing 304 can be associated with a tissue site having a smaller volume than the first dressing 302.
  • the tissue site covered by the second dressing 304 may have a smaller area and/or smaller depth than the tissue site covered by the first dressing 302.
  • the tissue site covered by the first dressing 302 may be a large abdominal wound, and the tissue site covered by the second dressing 304 may be a smaller site on the chest or back.
  • the flow restrictor 306 can be positioned in the open position of Figure 5, permitting fluid to be delivered to both the first dressing 302 and the second dressing 304. As fluid is provided, a user can observe the second dressing 304.
  • the therapy system 100 can determine if the first dressing 302 is full, storing the total volume of fluid delivered to both the first dressing 302 and the second dressing 304. For example, the therapy system 100 can operate in a “Fill Assist” mode to determine the total volume of fluid instilled to the first dressing 302 and the second dressing 304.
  • the user may manually start the flow of fluid to the tissue sites while monitoring the tissue sites to determine when an appropriate amount of fluid has been delivered. The user may then stop the flow of fluid.
  • the therapy system 100 may monitor the rate of fluid flow while flow is distributed to determine a total volume of fluid delivered to the tissue sites.
  • the therapy system 100 may store the total volume of fluid delivered and automatically deliver the same total volume of fluid in subsequent instillation therapy cycles.
  • the fluid can be left at the first dressing 302 and the second dressing 304 for a soak period.
  • the therapy system 100 may instill fluid to the first dressing 302 and the second dressing 304 and allow the fluid to remain at the first dressing 302 and the second dressing for a predetermined period, such as about 5 to about 10 minutes.
  • the therapy system 100 may then operate a negative-pressure therapy cycle.
  • the therapy system 100 can remove the instilled fluid from the first dressing 302 and the second dressing 304.
  • the negative-pressure source 102 can be operated to draw fluid from the first dressing 302 and the second dressing 304 through the bridge 1002.
  • a negative pressure can be generated at the first dressing 302 and the second dressing 304 according to a negative-pressure therapy protocol.
  • the flow restrictor 306 can be positioned to restrict flow to the second dressing 304.
  • the roller 512 can be positioned in the restricted position of Figure 9.
  • the flow rate through the lumen 518 of the third arm 408 is less than the flow rate through the second arm 406.
  • Both the first dressing 302 and the second dressing 304 can fill with fluid at approximately the same time due to the difference in flow rates in subsequent cycles.
  • operation of the flow restrictor 306 can be electronic.
  • the flow restrictor 306 can include one or more controllers and operational motors.
  • the controllers and operational motors can be communicatively coupled to the controller 108.
  • one or more sensors can be located on the flow restrictor 306 and provide signals to the controller 108.
  • the signals can provide information to the controller 108 indicative of position, flow rate, pressure, and other suitable variables.
  • the controller 108 can select operational positions for the flow restrictor 306 in response to the signals received from the flow restrictor 306.
  • the controller 108 can provide signals to the flow restrictor 306 for its operation.
  • the flow restrictor 306 may include a sensor configured to determine a flow rate of fluid passing through the flow restrictor 306.
  • the controller 108 may receive a signal reflecting the flow rate through the flow restrictor 306, and in response, the controller 108 may determine a total volume of fluid to pass through the flow restrictor 308 during a “Fill Assist” mode. The controller 108 may then operate the flow restrictor 306 in subsequent cycles to reduce the total volume of fluid passing through the flow restrictor 306 during an instillation cycle to total volume delivered to the second dressing 304 during the “Fill Assist” mode.
  • the flow restrictor 306 was positioned in a first restricted position, permitting about 50 ml/min of fluid flow through the lumen 518 of the third arm 408. Fluid flow through the second arm 406 was unrestricted and about 60 ml/ min. Fluid was provided to the first arm 404 of the T-fitting 402 at about 166 ml/min for about two minutes. The first dressing 302 filled with about 120 ml of fluid and the second dressing 304 fdled with about 100 ml of fluid. In another example embodiment, the flow restrictor 306 was positioned in a second restricted position, permitting 40 ml/min of fluid flow through the lumen 518 of the third arm 408.
  • Fluid flow through the second arm 406 was unrestricted and about 60 ml/ min. Fluid was provided to the first arm 404 of the T-fitting 402 at 166 ml/min for about two minutes.
  • the first dressing 302 filled with about 120 ml of fluid and the second dressing 304 filled with about 80 ml of fluid.
  • the flow restrictor 306 was positioned in a third restricted position, permitting 30 ml/min of fluid flow through the lumen 518 of the third arm 408. Fluid flow through the second arm 406 was unrestricted and about 60 ml/ min. Fluid was provided to the first arm 404 of the T-fitting 402 at 166 ml/min for about two minutes.
  • the first dressing 302 filled with about 120 ml of fluid and the second dressing 304 filled with about 60 ml of fluid.
  • the flow restrictor 306 was positioned in a fourth restricted position, permitting 10 ml/min of fluid flow through the lumen 518 of the third arm 408. Fluid flow through the second arm 406 was unrestricted and about 60 ml/ min. Fluid was provided to the first arm 404 of the T-fitting 402 at 166 ml/min for about two minutes.
  • the first dressing 302 filled with about 120 ml of fluid and the second dressing 304 filled with about 20 ml of fluid.
  • Fluid may be drawn off from the first dressing 302 and the second dressing 304 through the first connector 312 and the third connector 316 into the first end 1004 and the second end 1006 of the bridge 1002.
  • the bridge 1002 can provide an open pathway for the movement of fluid from the first dressing 302 and the second dressing 304.
  • the bridge 1002 can maintain an open pathway while subjected to a force. For example, a patient confined to a bed may roll over onto the bridge 1002.
  • the Bridge 1002 can maintain an open pathway while subjected to the body weight of the patient resting on the bridge 1002.
  • the bridge 1002 can also aid in the maintenance of an open pathway through the second arm 406 and the third arm 408 through the spatial coupling by the mounting bracket 1206.
  • the bridge 1002 can prevent the second arm 406 and the third arm 408 from becoming kinked or pinched due in the event a patient rests on the bridge 1002, the second arm 406, and the third arm 408.
  • FIG 14 is a perspective view of the bridge 1002 illustrating additional details that may be associated with some embodiments.
  • the bridge 1002 can be used without the flow restrictor 306 and the T-fitting 402.
  • the bridge 1002 can provide negative-pressure therapy to both the first dressing 302 and the second dressing 304 independent of the provision of instillation therapy.
  • the first end 1004 of the bridge can be fluidly coupled to the first connector 312 and the second end 1006 of the bridge 1002 can be fluidly coupled to the third connector 316.
  • the tube 1008 can be fluidly coupled to the negative-pressure source 102 and fluid may be drawn from the first dressing 302 and the second dressing 304 through the first connector 312 and the third connector 316 into the first end 1004 and the second end 1006 of the bridge 1002. Fluid may then be conducted to a canister, such as the container 106 for storage.
  • Figure 15 is a perspective view of the bridge 1002 illustrating additional details that may be associated with some embodiments. As illustrated in Figure 15, the bridge 1002 can be used without the flow restrictor 306 and the T-fitting 402. In some embodiments, the tube 1008 can be positioned in the second end 1006.
  • the third connector 316 may be uncoupled from the second end 1006, and the tube 1008 can be fluidly coupled to the second end 1006.
  • the tube 1008 can be fluidly coupled to the tube 1116.
  • the first end 1004 can be fluidly coupled to the first dressing 302.
  • the bridge 1002 can provide negative-pressure therapy to the first dressing 302 independent of the provision of instillation therapy and the second dressing 304.
  • the bridge 1002 can provide an open pathway while subjected to a force, such as a body weight of a patient resting on the bridge 1002 while providing negative-pressure therapy to the first dressing 302.
  • Figure 16 is an assembly view of another example of a fluid conductor 1600having a low-profile structure that may be associated with some example embodiments of the therapy system 100.
  • the fluid conductor 1600 comprises two spacer layers - a spacer layer 1602 and a spacer layer 1604 - disposed between the first layer 1606 and the second layer 1608.
  • Standoffs 1610 may be formed in each of the spacer layer 1602 and the spacer layer 1604.
  • the standoffs 1610 in the spacer layer 1602 are configured to extend toward the spacer layer 1604, and the standoffs 1610 in the spacer layer 1604 are configured to extend toward the spacer layer 1602.
  • the first layer 1606 may have a passage 1612, and the spacer layer 1602 may have a passage 1614, through which fluids may flow to the dressing interface 206.
  • the first layer 1606 and the spacer layer 1602 may additionally have a passage 1616 and a passage 1618, respectively, which may also be fluidly coupled to the dressing interface 206.
  • the fluid conductor 1600 may further comprise a fluid exit bond 1620 to prevent leakage of fluids flowing through the passage 1612 and the passage 1614.
  • the spacer layer 1604 may have an aperture 1622 concentric with the aperture 1624 of the second layer 1608.
  • the fluid conductor 1600 may further comprise a fluid exit bond 1626, which can prevent leakage of fluids flowing through the aperture 1624 and the aperture 1622.
  • a bridge cover 1628 may provide additional protection and support over the applicator 1702 if the fluid conductor 1600 is applied to a tissue site.
  • the bridge cover 1628 may also cover any adhesive that might be exposed from applying the fluid conductor 1600 to atissue site.
  • the bridge cover 1628 may be apolymer, such as a polyurethane film.
  • Figure 17 is a segmented view of an assembled portion of the fluid conductor 1600 in the example of Figure 16, illustrating additional details that may be associated with some embodiments.
  • the first layer 1606, second layer 1608, the spacer layer 1602, and the spacer layer 1604 may be assembled in a stacked relationship.
  • the first layer 1606 may be coupled to the spacer layer 1602
  • the second layer 1608 may be coupled to the spacer layer 1604
  • a periphery of the spacer layer 1602 may be coupled to a periphery of the spacer layer 1604 to form the flange 1704.
  • the spacer layer 1602 and the spacer layer 1604 can be coupled to form a liquid barrier defining a fluid path along a longitudinal axis of the fluid conductor 1600.
  • the fluid conductor 1600 may additionally comprise at least one barrier or wall, such as a first wall 1706, interior to the flange 1704.
  • the first wall 1706 may be formed by coupling the spacer layer 1602 and the spacer layer 1604.
  • the spacer layer 1602 may be welded to the spacer layer 1604 to form the first wall 1706.
  • the first wall 1706 may extend lengthwise through the fluid conductor 1600 into the applicator 1702 to form at least two fluid paths between the spacer layer 1602 and the spacer layer 1604 within the fluid conductor 1600.
  • the fluid conductor 1600 may further comprise a second barrier, such as a second wall 1708.
  • the second wall 1708 may be formed by coupling the spacer layer 1602 and the spacer layer 1604. In some embodiments, the second wall 1708 also may extend lengthwise through the fluid conductor 1600 into the applicator 1702. In some example embodiments, the first wall 1706 and the second wall 1708 may comprise a polymeric film coupled between the first layer 1606 and the second layer 1608. In some other example embodiments, the first wall 1706 and the second wall 1708 may comprise a weld (RF or ultrasonic), a heat seal, an adhesive bond, or a combination of any of the foregoing.
  • RF or ultrasonic RF or ultrasonic
  • barriers or walls interior to the flange 1704 may form fluid pathways between the spacer layer 1602 and the spacer layer 1604.
  • first wall 1706 and the second wall 1708 cooperate with the flange 1704 to form a first fluid conductor 1710, a second fluid conductor 1712, and a third fluid conductor 1714.
  • the first fluid conductor 1710 and the second fluid conductor 1712 may be coupled to a sensor to measure pressure
  • the third fluid conductor 1714 may be coupled to a negative-pressure source.
  • the first fluid conductor 1710 and the second fluid conductor 1712 may have a height having a value in a range between about 0.25 mm and about 3 mm.
  • the first fluid conductor 1710 and the second fluid conductor 1712 may have a width having a value in a range between about 1 mm and about 7.5 mm.
  • the first fluid conductor 1710 and the second fluid conductor 1712 may have a cross-sectional area having a value in a range between about 0.17 mm 2 and 16.77 mm 2 .
  • the first fluid conductor 1710 and the second fluid conductor 1712 may have a cross-sectional area having a value in a range between about 0.1 mm 2 and 18 mm 2 .
  • each of the first wall 1706 and the second wall 1708 may extend an angular distance around the proximal end of the applicator 1702 and cooperate with blocking walls of the flange 1704, such as blocking walls 1716, to form extensions of the first fluid conductor 1710 and the second fluid conductor 1712.
  • the extensions may be fluidly coupled to the recessed space 1718.
  • the first fluid conductor 1710 and the second fluid conductor 1712 are fluidly coupled to the recessed space 1718 through passages, such as a through-hole 1720 and a through- hole 1722, respectively.
  • at least some of the supports may be disposed in one or both of the first fluid conductor 1710 and the second fluid conductor 1712.
  • some of the supports may be formed by the standoffs 1610 disposed between the flange 1704 and the first wall 1706, and between the flange 1704 and the second wall 1708. Additionally or alternatively, the thickness of the spacer layer 1604 may be increased to provide additional structural support to the first fluid conductor 1710 and the second fluid conductor 1712.
  • the first fluid conductor 1710 and the second fluid conductor 1712 may comprise or be formed by tubes through or along the fluid conductor 1600. Some configurations may not have the first fluid conductor 1710 or the second fluid conductor 1712, or may have only one of the first fluid conductor 1710 and the second fluid conductor 1712.
  • Each of the first wall 1706 and the second wall 1708 can extend at least partially around the proximal end of the applicator 1702 that form the first fluid conductor 1710 and the second fluid conductor 1712.
  • each of the first wall 1706 and the second wall 1708 can extend from about 45° to about 315° from the center of the third fluid conductor 1714 where the third fluid conductor 1714 is in fluid communication with the recessed space 1718.
  • the angular distance may be different for each of the first fluid conductor 1710 and the second fluid conductor 1712.
  • the angular distance for each of the first fluid conductor 1710 and the second fluid conductor 1712 may be about 60° and 210°, respectively, from the third fluid conductor 1714.
  • the through-hole 1720 and the through-hole 1722 may be separated from each other by an angular distance of at least 90°, extending around the applicator 1702 in a direction away from the third fluid conductor 1714.
  • the spacing and disposition of the through-hole 1720 and the through-hole 1722 from each other, and from the third fluid conductor 1714, can allow the first fluid conductor 1710 and the second fluid conductor 1712 to better avoid the flow of fluids passing through from the tissue interface 114 to the third fluid conductor 1714 when negative pressure is applied.
  • the through-hole 1720 and the through-hole 1722 may be sufficiently small for further restricting fluid flow into the first fluid conductor 1710 and the second fluid conductor 1712.
  • the through-hole 1720 and the through-hole 1722 may have a cross- sectional area having a value in a range between about 0.17 mm 2 and 16.77 mm 2 . In some embodiments, the through-hole 1720 and the through-hole 1722 may have a cross-sectional area having a value in a range between about 0.1 mm 2 and 18 mm 2 to further restrict fluid flow to the first fluid conductor 1710 and the second fluid conductor 1712 and impede the inflow of fluids and exudates without inhibiting pressure sensing within the recessed space 1718.
  • Figure 18 is a segmented perspective view of portion of the fluid conductor 1600 in the example of Figure 16, illustrating additional details that may be associated with some embodiments.
  • Figure 18 further illustrates an example of the dressing interface 206 and the conduit 235 coupled to the fluid conductor 1600.
  • Each of the first fluid conductor 1710 and the second fluid conductor 1712 may be fluidly coupled directly to the conduit 235 in some examples.
  • both of the first fluid conductor 1710 and the second fluid conductor 1712 may be fluidly coupled to a single space (not shown) within the dressing interface 206, which can be fluidly coupled to the conduit 235.
  • both the first fluid conductor 1710 and the second fluid conductor 1712 are fluidly separate from and parallel to the third fluid conductor 1714.
  • the parallel orientation can minimize the vertical profile of the fluid conductor 1600, while still being resistant to collapsing under pressure that could block fluid flow through the fluid pathways.
  • Figure 19 is a schematic view of an example configuration of fluid pathways in the fluid conductor 1600 of Figure 16 as assembled, illustrating additional details that may be associated with some embodiments.
  • Figure 20 is a schematic view taken along line 20 — 20
  • Figure 21 is a schematic view taken along line 21 — 21.
  • the supports 1724 may have a variety of shapes, and may be sized and arranged in different patterns within the third fluid conductor 1714. For example, as illustrated in the examples of Figure 20 and Figure 21, some of the supports 1724 may extend from the first layer 1606 and some of the supports 1724 may extend from the second layer 1608. In some embodiments, some of the supports 1724 may be opposingly aligned.
  • the supports 1724 can extend from the first layer 1606 towards some of the supports 1724 extending from the second layer 1608, and some of the supports 1724 in opposition may contact each other.
  • the fluid conductor 1600 may include more than one row of the supports 1724.
  • the fluid conductor 1600 has four rows of the supports 1724, and the supports 1724 forming outside rows are offset or staggered from the supports 1724 forming the two inside rows.
  • Each of the first wall 1706 and the second wall 1708 cooperate with the flange 1704 to form the first fluid conductor 1710 and the second fluid conductor 1712.
  • some of the supports 1724 maybe disposed within one or both of the first fluid conductor 1710 and the second fluid conductor 1712.
  • the supports 1724 disposed in the third fluid conductor 1714 may have a larger diameter and pitch than the supports 1724 in the first fluid conductor 1710 and the second fluid conductor 1712, and may increase fluid flow to facilitate the removal of fluids and exudates within the recessed space 1718.
  • the supports 1724 in the first fluid conductor 1710 and the second fluid conductor 1712 may have a noticeably smaller diameter and pitch than the supports 1724 in the third fluid conductor 1714, and may restrict fluid flow to facilitate pressure sensing within the recessed space 1718 while impeding the inflow of fluids and exudates into the first fluid conductor 1710 and the second fluid conductor 1712.
  • the arrangement and dimensions of the supports 1724 may be tailored to manage the delivery of negative pressure to the tissue interface 114 and the measurement of pressure within the recessed space 1718.
  • the fluid conductor 1600 can be used with the flow restrictor 306.
  • a first fluid conductor 1600 can be fluidly coupled to the second arm 406 and a second fluid conductor 1600 can be fluidly coupled to the third arm 408 between the flow restrictor 306 and the second dressing 304.
  • the therapy system 100 can operate as previously described to instill fluid to the first dressing 302 and the second dressing 304.
  • the fluid conductor 1600 can also be used in place of the bridge 1002.
  • the tube 1008 can be fluidly coupled to a T- fitting.
  • a first fluid conductor 1600 and a second fluid conductor 1600 can be fluidly coupled to the T- fitting and negative -pressure can be provided to the first dressing 302 and the second dressing 304 as previously described.
  • multiple fluid conductors can be used to provide both negative-pressure therapy and instillation therapy with the flow restrictor 306.
  • Figure 22 is a schematic view of the therapy system 100 deployed on a patient, such as the patient 2202.
  • the first dressing 302 can be deployed at a first tissue site, and the second dressing 304 can be deployed at a second tissue site.
  • the first connector 312 can be coupled to the first dressing 302 and further fluidly coupled to the first end 1004 of the bridge 1002.
  • the third connector 316 can be coupled to the second dressing 304 and further fluidly coupled to the second end 1006 of the bridge 1002.
  • the second arm 406 can be fluidly coupled to the first connector 312, and the third arm 408 can be fluidly coupled to the second connector 314.
  • the second connector 314 can be coupled to the second dressing 304.
  • the first arm 404 can be fluidly coupled to the fluid source 118 of the therapy system 100, and the tube 1008 can be fluidly coupled to the container 106 of the negative-pressure source 102 of the therapy system 100.
  • the therapy system 100 can provide negative-pressure therapy and instillation therapy to the first dressing 302 and the second dressing 304.
  • a clinician can monitor fluid delivery to the first dressing 302 and the second dressing 304. As the second dressing 304 fills or approaches being full, the clinician can operate the flow restrictor 306 to block the third arm 408, to prevent overfill of the second dressing 304 while allowing the first dressing 302 to continue to receive instillation fluids.
  • the therapy system 100 can determine a volume size of the first dressing 302 and the second dressing 304 in response to the amount of fluid delivered during the instillation therapy cycle.
  • the flow restrictor 306 can be operated by the clinician to a flow rate that will provide the appropriate amount of fluid to the second dressing 304 in future instillation therapy cycles.
  • Figure 23 is a schematic view of a portion of a leg 2302 having the therapy system 100 deployed on two tissue sites.
  • the first dressing 302 can be deployed at a first tissue site, and the second dressing 304 can be deployed at a second tissue site.
  • the first connector 312 can be coupled to the first dressing 302 and further fluidly coupled to the second arm 406.
  • the third arm 408 can be fluidly coupled to the second connector 314.
  • the second connector 314 can be coupled to the second dressing 304.
  • the first arm 404 can be fluidly coupled to the fluid source 118 of the therapy system 100.
  • the therapy system 100 can provide instillation therapy to the first dressing 302 and the second dressing 304.
  • a clinician can monitor fluid delivery to the first dressing 302 and the second dressing 304. As the second dressing 304 fills or approaches being full, the clinician can operate the flow restrictor 306 to block the third arm 408, to prevent overfill of the second dressing 304 while allowing the first dressing 302 to continue to receive instillation fluids.
  • the therapy system 100 can determine a volume size of the first dressing 302 and the second dressing 304 in response to the amount of fluid delivered during the instillation therapy cycle.
  • the flow restrictor 306 can be operated by the clinician to a flow rate that will provide the appropriate amount of fluid to the second dressing 304 in future instillation therapy cycles.
  • the first dressing 302 and the second dressing 304 may be disposed on a same tissue site.
  • the first dressing 302 and the second dressing 304 may be disposed on opposite ends of the tissue site.
  • the therapy system 100 may supply fluid to the tissue site through both the first dressing 302 and the second dressing 304 to increase fluid coverage of the tissue site by supplying fluid at multiple locations.
  • a therapy system is provided that permits fluid management of both negative- pressure therapy systems and instillation therapy systems without requiring changeover of systems.
  • the system described herein can provide management of fluids for two tissue sites having uneven shapes and differing sizes, and differing volumes, or for a tissue site involving a joint by providing a flow control device to permit metering of fluid to at least one of the tissue sites.
  • specific flow rates can be selected for at least one of the tissue sites.
  • the system provides bridging capability for tissue sites having fragile skin that can make bridging of two or more tissue sites difficult or uncomfortable for the patient. Simultaneous treatment of multiple tissue sites can be accomplished without requiring additional layers, such as a protective layer to be included with the dressing.

Landscapes

  • Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Fluid Mechanics (AREA)
  • Pulmonology (AREA)
  • Media Introduction/Drainage Providing Device (AREA)

Abstract

L'invention concerne un système d'instillation d'au moins deux sites tissulaires. Le système peut inclure un premier pansement, un second pansement, et un pont. Le pont peut être configuré pour coupler fluidiquement le premier pansement et le second pansement. Le pont peut en outre être conçu pour être couplé de manière fluidique à une source d'instillation. Le système peut comprendre un dispositif de restriction de fluide couplé au pont entre la source d'instillation et le premier pansement. Le dispositif de restriction de fluide peut être utilisé pour permettre de manière sélective l'écoulement de fluide vers le premier pansement.
PCT/IB2021/053130 2020-04-22 2021-04-15 Pansement en pont pour l'irrigation de multiples sites tissulaires WO2021214609A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063014022P 2020-04-22 2020-04-22
US63/014,022 2020-04-22

Publications (1)

Publication Number Publication Date
WO2021214609A1 true WO2021214609A1 (fr) 2021-10-28

Family

ID=75625619

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2021/053130 WO2021214609A1 (fr) 2020-04-22 2021-04-15 Pansement en pont pour l'irrigation de multiples sites tissulaires

Country Status (1)

Country Link
WO (1) WO2021214609A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006026904A1 (fr) * 2004-09-09 2006-03-16 Jihan Cai Dispositif de perfusion sur jetable
US8974428B2 (en) * 2011-11-01 2015-03-10 J&M Shuler Medical, Inc. Mechanical wound therapy for sub-atmospheric wound care system
WO2019190753A1 (fr) * 2018-03-29 2019-10-03 Kci Licensing, Inc. Système de gestion d'une thérapie d'instillation sur des plaies multiples avec une source de fluide unique

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006026904A1 (fr) * 2004-09-09 2006-03-16 Jihan Cai Dispositif de perfusion sur jetable
US8974428B2 (en) * 2011-11-01 2015-03-10 J&M Shuler Medical, Inc. Mechanical wound therapy for sub-atmospheric wound care system
WO2019190753A1 (fr) * 2018-03-29 2019-10-03 Kci Licensing, Inc. Système de gestion d'une thérapie d'instillation sur des plaies multiples avec une source de fluide unique

Similar Documents

Publication Publication Date Title
EP3813750B1 (fr) Doublure détachable dotée d'une protection de bord
US20200000643A1 (en) Long-Duration, Deep Wound Filler With Means To Prevent Granulation In-Growth
EP3169382A1 (fr) Cartouche d'instillation pour l'administration de fluide actionnée par le vide
US20220305192A1 (en) Abdominal Negative-Pressure Therapy Dressing With Closed-Loop Force Management Control
WO2019152422A1 (fr) Pansement permettant la rupture de débris au niveau d'un site tissulaire
US20240131249A1 (en) Systems, apparatuses, and methods for negative-pressure treatment with reduced tissue in-growth and extended wear time
WO2021214609A1 (fr) Pansement en pont pour l'irrigation de multiples sites tissulaires
US20230405211A1 (en) Low profile off-loading fluid and pressure conduit
WO2019067154A1 (fr) Interface, systèmes et méthodes de pansement
US11969542B2 (en) System and apparatus for preventing therapy unit contamination
US20230285199A1 (en) Offloading accessory for use with negative-pressure wound therapy dressings and systems
US11771817B2 (en) Systems and methods for instillation purging
US20220387696A1 (en) Fluid bridge configured for use vertically and/or under compression
WO2023166393A1 (fr) Appareil et système de gestion de tube au niveau d'un site tissulaire
WO2021209951A1 (fr) Ensemble de tubes pour la surveillance de la pression
WO2023227973A1 (fr) Dispositif de macro-déformation indépendant
WO2023166392A1 (fr) Système de traitement de plaie par pression négative
WO2023079382A1 (fr) Pansement de thérapie de plaie à pression négative avec super-absorbant isolé
WO2024013685A1 (fr) Système en boucle fermée pour détermination de volume d'instillation optimale pour instillation avec un traitement de plaie par pression négative
WO2024023650A1 (fr) Appareil, systèmes et procédés de purge d'une cartouche d'exsudat

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21720577

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21720577

Country of ref document: EP

Kind code of ref document: A1